Clinical trials: Germ Cell Tumor
Glioblastoma
CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
This is a first-in-human study of CM93, an oral investigational drug, in adults with Epidermal Growth Factor Receptor-modified glioblastoma.
- Trial name
- NCT04933422
- Testing
- CM93
- Volunteers
- 72 people
- Sponsor
- Crimson Biopharm Inc.
Glioblastoma
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
This study is a phase I, open label trial to determine the Maximum Tolerated Dose (MTD), safety, pharmacokinetics, and efficacy of BIBW 2992 (an epidermal growth factor receptor(EGFR)inhibitor) to be used in combination with…
- Trial name
- NCT00977431
- Testing
- Temozolomide, Radiotherapy, BIBW2992
- Where
- 5 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Melanoma
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
This is a safety and efficacy study of different administration regimens of nivolumab plus Ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma.
- Trial name
- NCT02905266
- Testing
- Nivolumab, Ipilimumab
- Where
- 16 sites in Australia, France and 2 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
Substudy 02D is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04700072
- Testing
- Pembrolizumab, Pembrolizumab/Quavonlimab, Lenvatinib
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioma, Medulloblastoma
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
This study will assess the rate of objective confirmed tumor response of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma and in children with newly diagnosed high-grade glioma.
- Trial name
- NCT00404495
- Testing
- Irinotecan, Temozolomide
- Where
- 29 sites in Australia, Belgium and 6 more
- Volunteers
- 83 people
- Sponsor
- Pfizer
Brain and Central Nervous System Tumors
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of leflunomide in treating patients who have anaplastic…
- Trial name
- NCT00003775
- Testing
- leflunomide
- Where
- 26 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Pfizer
Melanoma
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
- Trial name
- NCT04370704
- Testing
- INCAGN02385, INCAGN02390, INCMGA00012.
- Where
- 17 sites in United States, Australia
- Volunteers
- 61 people
- Sponsor
- Incyte Corporation
Glioblastoma Multiforme
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
The overall purpose of the study is to investigate the efficacy and safety of ALECSAT in patients with relapse of GlioBlastoma Multiforme (GBM) after first line treatments (followed by reoperation if possible).
- Trial name
- NCT02060955
- Testing
- ALECSAT, Bevacizumab/Irinotecan
- Where
- 4 sites in Denmark
- Volunteers
- 25 people
- Sponsor
- CytoVac A/S
Neuroendocrine Tumors
Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice
The main aim of this study is to assess the Progression-Free Survival (PFS) at 12 months of Lanreotide Autogel 120 mg use when administered as part of routine GEP-NET treatment and to follow patient treatment pathways, identify…
- Trial name
- NETways (NCT03895463)
- Where
- 11 sites in Poland
- Sponsor
- Ipsen
Glioblastoma, GBM
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to see if it is useful in treating glioblastoma following standard of care therapy surgery and chemoradiation.
- Trial name
- NCT07225621
- Testing
- 5-ALA HCl + LIDU SDT
- Where
- 11 sites in United States
- Volunteers
- 103 people
- Sponsor
- Alpheus Medical, Inc.
Dermoid
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy
- Trial name
- MP-VAC-206 (NCT06219733)
- Testing
- Vactosertib, Imatinib
- Where
- South Korea
- Sponsor
- MedPacto, Inc.
Melanoma
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
This research is being done to find out the safety of MORAb-028 in subjects with metastatic melanoma.
- Trial name
- NCT01123304
- Testing
- MORAb028
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Morphotek
Advanced Solid Tumors, Head and Neck Cancer
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- FPA008-003 (NCT02526017)
- Testing
- Cabiralizumab, Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 313 people
- Sponsor
- Five Prime Therapeutics, Inc.
Melanoma
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
This is an observational, national, retrospective study consisting of pediatric patients with advanced (spread or unremoveable) melanoma identified in the DMTR in the Netherlands
- Trial name
- NCT04196452
- Testing
- Ipilimumab
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin), Intraocular Melanoma
Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation
The purpose of this study is to evaluate the safety and immunogenicity of a DNA vaccine encoding a melanosomal antigen in melanoma patients at risk for disease progression or recurrence.
- Trial name
- NCT00471133
- Testing
- Xenogeneic Tyrosinase DNA Vaccine, TriGrid Delivery System for Intramuscular Electroporation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ichor Medical Systems Incorporated
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Glioblastoma Multiforme
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with…
- Trial name
- NCT02704858
- Testing
- Perillyl alcohol
- Where
- 11 sites in United States
- Volunteers
- 49 people
- Sponsor
- Neonc Technologies, Inc.
Melanoma
A Study of GC101 TIL in Advanced Melanoma
98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months
- Trial name
- MIZAR-003 (NCT06703398)
- Testing
- GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Juncell Therapeutics
Recurrent Glioblastoma Multiforme (GBM)
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
This was an investigational study to assess the objective overall response (OOR) rate (complete response [CR] + partial response [PR]) of imatinib mesylate and hydroxyurea (hydroxycarbamide) combination therapy in patients with…
- Trial name
- NCT00290771
- Testing
- Imatinib tablets, Hydroxyurea capsules
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- Novartis
Melanoma
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) of relatlimab in combination with ipilimumab.
- Trial name
- NCT03978611
- Testing
- Relatlimab, Ipilimumab
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 11 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.